Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Sponsored by Revolution Medicines, Inc.
About this study
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents or as a monotherapy to be evaluated in patients with RAS-mutated solid tumors with a focus on NSCLC. This is an open-label platform Phase 1b/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC), or as a monotherapy and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with KRAS or RAS mutations will be specified in each subprotocol. Subprotocol A is an open-label, multicenter, Phase 1b/2 study of RMC-6291, with or without RMC-6236, in combination with pembrolizumab, with or without chemotherapy, in patients with KRAS G12C-mutated advanced solid …
Where this study is enrolling (23)
- Call +1 480-256-6444
Banner MD Anderson Cancer Center
Gilbert, Arizona
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
UCSF Medical Center - Mission Bay
San Francisco, California
- I'm interested
UC Davis, Davis Comprehensive Cancer Center
Sacramento, California
- I'm interested
Stanford University - Stanford Cancer Institute
Stanford, California
- I'm interested
City of Hope - Duarte
Duarte, California
Show all 23 locations
- I'm interested
City of Hope - Lennar
Irvine, California
- I'm interested
University of California, San Diego Moores Cancer Center
San Diego, California
- I'm interested
Georgetown University Medical Center
Washington D.C., District of Columbia
- I'm interested
Boca Raton Clinical Research Associates
Plantation, Florida
- I'm interested
Cancer Specialists of North Florida
Saint Augustine, Florida
- I'm interested
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
- I'm interested
Dana Farber Cancer Institute
Boston, Massachusetts
- I'm interested
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan
- I'm interested
Intermountain Health - St. Vincent Frontier Cancer Center
Billings, Montana
- I'm interested
Icahn School of Medicine at Mount Sinai
New York, New York
- Call 516-488-2918
Clinical Research Alliance
Westbury, New York
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
Columbia University Medical Center
New York, New York
- I'm interested
New York University Langone Health
New York, New York
- Call 216-844-3951
University Hospitals Cleveland Medical Center
Cleveland, Ohio
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
- I'm interested
The University of Texas MD Anderson Cancer Center
Houston, Texas
- I'm interested
NEXT Oncology Dallas
Irving, Texas
- I'm interested
NEXT Oncology Virginia
Fairfax, Virginia
Who can participate
Inclusion criteria
- ✓All Patients (unless otherwise noted):
- ✓≥ 18 years of age
- ✓ECOG PS is 0 to 1
- ✓Adequate organ function as outlined by the study
- ✓Received prior standard therapy appropriate for tumor type and stage
- ✓Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
- ✓Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
- ✓Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)
Exclusion criteria
- ✕All Patients:
- ✕Primary central nervous system (CNS) tumors
- ✕Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
- ✕Major surgery \< 28 days of first dose
- ✕Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids
- ✕Other inclusion/exclusion criteria may apply.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.